3 terminated, 1 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 3, Completed 1 |
Follow Complexa, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral CXA-10 in Pulmonary Arterial Hypertension CXA-10 - Pulmonary Arterial Hypertension | Phase 2 | Terminated | Gladwin, Mark, MD | 1 | 2019-10-31 | 2022-01-12 |
| CXA-10 Study in Subjects With Pulmonary Arterial Hypertension CXA-10 - PAH | Phase 2 | Terminated | Complexa, Inc. | 33 | 2019-08-09 | 2020-08-26 |
| PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH) 75mg CXA-10, 150mg CXA-10, Placebo - PAH | Phase 2 | Terminated | Complexa, Inc. | 69 | 2018-08-01 | 2020-08-10 |
| FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) CXA-10 - Primary Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Complexa, Inc. | 33 | 2018-04-15 | 2020-08-03 |
Pulmonary Arterial Hypertension (3) · Cardiovascular Diseases (2) · Connective Tissue Diseases (2) · Familial Primary Pulmonary Hypertension (2) · Hypertension (2) · Hypertension, Pulmonary (2) · Lung Diseases (2) · Vascular Diseases (2) · Kidney Diseases (1) · Nephrotic Syndrome (1) · Proteinuria (1)
CXA-10 (4)
United States (4) · United Kingdom (2)
Theo Danoff, MD (2) · Marc Simon, MD (1) · Theodore Danoff, MD (1)
P01HL103455 (1)